The Lung Institute is opening its fifth clinic soon in Dallas, Texas. The Lung Institute welcomes the new Dallas-based staff, and is excited to provide new jobs in the area along with alternative treatment options for those who suffer from debilitating lung disease in the surrounding area.The Lung Institute helps those who suffer from debilitating lung diseases like chronic obstructive pulmonary disease (COPD), interstitial lung disease and pulmonary fibrosis using stem cell therapy. The majority of patients treated with this minimally invasive, outpatient therapy see an improved quality of life after receiving treatment. The company is excited to see the Lung institute TX Location come online to help surrounding residents breathe easier.

COPD in Texas

COPD is one of the most common lung diseases, typically caused by cigarette smoking. In 2014 a report published by the American Lung Association reported 87,305 cases of COPD in Dallas. In the state of Texas, 5.7 percent, or 1,000,072 Texas adults are estimated to have COPD, according to theTexas Department of State Health Services. COPD is a progressive form of lung disease ranging from mild to severe. It is characterized by a restriction of airflow into and out of the lungs that makes breathing difficult.

Interstitial Lung Disease in Texas

The term interstitial lung disease encompasses over 100 different types of pulmonary disorders affecting the absorption of oxygen into the lungs. It includes a diverse collection of illnesses with a variety of causes, treatments and prognoses. Individuals who suffer from interstitial lung disease often have difficulty breathing and moving from place to place due to chronic shortness of breath. Disorders classified under interstitial lung disease are characterized by scarring of the lung’s delicate tissues and a dry, pestering cough.

Pulmonary Fibrosis in Texas

Pulmonary fibrosis scars the lungs, causing intricate pulmonary passageways to thicken and harden, obstructing the free passage of oxygen through the walls of the lungs’ tiny air sacs (alveoli), and into the bloodstream. The resulting lack of oxygen in the bloodstream leaves pulmonary fibrosis sufferers short of breath even after periods of prolonged rest. Idiopathic pulmonary fibrosis is a form of pulmonary fibrosis with no known cause. Pulmonary fibrosis is a progressive disease that varies in the rate of degeneration from person to person.

Traditional Options

Traditional lung disease treatment options in Texas include medications, supplemental oxygen, and, in severe cases, a lung reduction or transplant. These options either are either high-risk or accomplish nothing more than masking symptoms of disease. For example, roughly 78 percent of patients survive the first year after receiving a lung transplant, and this percentage decreases with each following year. About 63 percent survive 3 years after the surgery, and about 51 percent make it to 5 years.

A Better Option

The Lung Institute clinic in Texas provides stem cell therapy using cells extracted from a patient’s own body–from blood, fat tissue or bone marrow. The cells are then treated and reintroduced into the body. Once back in circulation, stem cells naturally target damaged lung tissue, which may lead to improved lung function.

The results speak for themselves. 70 percent of Lung Institute patients report an improved quality of life after receiving stem cell therapy. If you or a loved one suffers from lung disease, the Lung Institute location in Texas can help. Contact one of our patient coordinators at (800) 729-3065 for a free evaluation.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.